148 related articles for article (PubMed ID: 38347908)
1. Impact of Lung Function on Asthma Exacerbation Rates in Children Treated with Dupilumab: The VOYAGE Study.
Guilbert TW; Murphy KR; Hamelmann E; Ross KR; Gupta A; Fiocchi A; Xia C; Gall R; Ledanois O; Radwan A; Jacob-Nara JA; Rowe PJ; Deniz Y
J Asthma Allergy; 2024; 17():81-87. PubMed ID: 38347908
[TBL] [Abstract][Full Text] [Related]
2. Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study.
Bacharier LB; Guilbert TW; Katelaris CH; Deschildre A; Phipatanakul W; Liu D; Altincatal A; Mannent LP; Amin N; Laws E; Akinlade B; Jacob-Nara JA; Deniz Y; Rowe PJ; Lederer DJ; Hardin M
J Allergy Clin Immunol Pract; 2024 Apr; 12(4):948-959. PubMed ID: 38092225
[TBL] [Abstract][Full Text] [Related]
3. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma.
Bacharier LB; Maspero JF; Katelaris CH; Fiocchi AG; Gagnon R; de Mir I; Jain N; Sher LD; Mao X; Liu D; Zhang Y; Khan AH; Kapoor U; Khokhar FA; Rowe PJ; Deniz Y; Ruddy M; Laws E; Patel N; Weinreich DM; Yancopoulos GD; Amin N; Mannent LP; Lederer DJ; Hardin M;
N Engl J Med; 2021 Dec; 385(24):2230-2240. PubMed ID: 34879449
[TBL] [Abstract][Full Text] [Related]
4. Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma.
Bacharier LB; Pavord ID; Maspero JF; Jackson DJ; Fiocchi AG; Mao X; Jacob-Nara JA; Deniz Y; Laws E; Mannent LP; Amin N; Akinlade B; Staudinger HW; Lederer DJ; Hardin M
J Allergy Clin Immunol; 2024 Jan; ():. PubMed ID: 38272375
[TBL] [Abstract][Full Text] [Related]
5. Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma.
Papadopoulos NG; Szefler SJ; Bacharier LB; Maspero JF; Domingo C; Fiocchi A; Lee JK; Daizadeh N; Lederer DJ; Hardin M; Gall R; Djandji M; Siddiqui S; Jacob-Nara JA; Deniz Y; Rowe PJ
Allergy; 2023 Aug; 78(8):2157-2167. PubMed ID: 37059696
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline.
Bourdin A; Virchow JC; Papi A; Lugogo NL; Bardin P; Antila M; Halpin DMG; Daizadeh N; Djandji M; Ortiz B; Jacob-Nara JA; Gall R; Deniz Y; Rowe PJ
Respir Med; 2022 Oct; 202():106938. PubMed ID: 36087550
[TBL] [Abstract][Full Text] [Related]
7. Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma.
Papi A; Corren J; Castro M; Domingo C; Rogers L; Chapman KR; Jackson DJ; Daizadeh N; Pandit-Abid N; Gall R; Jacob-Nara JA; Rowe PJ; Deniz Y; Ortiz B
Allergy; 2023 Jan; 78(1):233-243. PubMed ID: 35899469
[TBL] [Abstract][Full Text] [Related]
8. Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma.
Corren J; Katelaris CH; Castro M; Maspero JF; Ford LB; Halpin DMG; Rice MS; Radwan A; Deniz Y; Rowe PJ; Teper A; Djandji M
Eur Respir J; 2021 Oct; 58(4):. PubMed ID: 34266940
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils.
Bleecker ER; Panettieri RA; Lugogo NL; Corren J; Daizadeh N; Jacob-Nara JA; Deniz Y; Rowe PJ; Khodzhayev A; Soler X; Ferro TJ; Hansen CN
J Immunol Res; 2023; 2023():9943584. PubMed ID: 37901346
[TBL] [Abstract][Full Text] [Related]
10. Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function.
Pavord ID; Siddiqui S; Papi A; Corren J; Sher LD; Bardin P; Langton D; Park HS; Rice MS; Deniz Y; Rowe P; Staudinger HW; Patel N; Ruddy M; Graham NMH; Teper A
J Asthma Allergy; 2020; 13():701-711. PubMed ID: 33364789
[TBL] [Abstract][Full Text] [Related]
11. Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma.
Corren J; Katelaris CH; Castro M; Maspero JF; Humbert M; Halpin DMG; Altincatal A; Pandit-Abid N; Soler X; Radwan A; Jacob-Nara JA; Deniz Y; Rowe PJ
ERJ Open Res; 2023 Sep; 9(5):. PubMed ID: 37859672
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction.
Hanania NA; Castro M; Bateman E; Pavord ID; Papi A; FitzGerald JM; Maspero JF; Katelaris CH; Singh D; Daizadeh N; Altincatal A; Pandit-Abid N; Soler X; Siddiqui S; Laws E; Jacob-Nara JA; Rowe PJ; Lederer DJ; Hardin M; Deniz Y
Ann Allergy Asthma Immunol; 2023 Feb; 130(2):206-214.e2. PubMed ID: 36332763
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study.
Fiocchi AG; Phipatanakul W; Zeiger RS; Durrani SR; Cole J; Msihid J; Gall R; Jacob-Nara JA; Deniz Y; Rowe PJ; Lederer DJ; Hardin M; Zhang Y; Khan AH
Eur Respir J; 2023 Nov; 62(5):. PubMed ID: 37734856
[TBL] [Abstract][Full Text] [Related]
14. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
Castro M; Corren J; Pavord ID; Maspero J; Wenzel S; Rabe KF; Busse WW; Ford L; Sher L; FitzGerald JM; Katelaris C; Tohda Y; Zhang B; Staudinger H; Pirozzi G; Amin N; Ruddy M; Akinlade B; Khan A; Chao J; Martincova R; Graham NMH; Hamilton JD; Swanson BN; Stahl N; Yancopoulos GD; Teper A
N Engl J Med; 2018 Jun; 378(26):2486-2496. PubMed ID: 29782217
[TBL] [Abstract][Full Text] [Related]
15. Effect of Dupilumab in Korean Patients With Uncontrolled Moderate-to-Severe Asthma: A LIBERTY ASTHMA QUEST Sub-analysis.
Rhee CK; Park JW; Park HW; Cho YS
Allergy Asthma Immunol Res; 2022 Mar; 14(2):182-195. PubMed ID: 35255536
[TBL] [Abstract][Full Text] [Related]
16. Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization.
Corren J; Jackson DJ; Casale TB; Borish L; Rabe KF; Busse WW; Maspero JF; Jackson DJ; Daizadeh N; Altincatal A; Radwan A; Khodzhayev A; Djandji M; Jacob-Nara JA; Rowe PJ; Deniz Y
J Asthma Allergy; 2023; 16():249-260. PubMed ID: 36915284
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study.
Tohda Y; Nakamura Y; Fujisawa T; Ebisawa M; Arima K; Miyata M; Takahashi Y; Rice MS; Deniz Y; Rowe P; Patel N; Graham NMH; Teper A
Allergol Int; 2020 Oct; 69(4):578-587. PubMed ID: 32444306
[TBL] [Abstract][Full Text] [Related]
19. Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma.
Papi A; Castro M; Corren J; Pavord ID; Tohda Y; Altincatal A; Pandit-Abid N; Laws E; Akinlade B; Mannent LP; Gall R; Jacob-Nara JA; Deniz Y; Rowe PJ; Lederer DJ; Hardin M
Respir Med; 2024 Apr; 224():107535. PubMed ID: 38272376
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose.
Domingo C; Maspero JF; Castro M; Hanania NA; Ford LB; Halpin DMG; Jackson DJ; Daizadeh N; Djandji M; Mitchell CP; Crikelair N; Jacob-Nara JA; Deniz Y; Rowe PJ; Ortiz B
J Allergy Clin Immunol Pract; 2022 Jul; 10(7):1835-1843. PubMed ID: 35398549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]